Skip to content

Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity

Observational, Prospective, Multicentric Study of the Effect of Bifidobacterium Longum 35624 on Quality of Life of Patients With Irritable Bowel Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04662502
Enrollment
220
Registered
2020-12-10
Start date
2018-11-22
Completion date
2020-06-26
Last updated
2021-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity

Detailed description

This observatory evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity, after a one-month treatment with Bibidobacterium longum 35624, 1x10\^9 CFU/capsule, 1 capsule/day.

Interventions

Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month

Sponsors

Biocodex
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, at least 18 years of age * Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV criteria * Having received a first prescription of Bifidobacterium longum 35624 during the consultation (independently of participation in the observatory) * Informed and having declared his/her non-opposition to the study.

Exclusion criteria

* Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook * Having already taken Bifidobacterium longum 35624 * Having received probiotics or antibiotics within 2 weeks previous * Having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation * Participant in another trial * Pregnant or breastfeeding women * Being under guardianship or curator. * Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook

Design outcomes

Primary

MeasureTime frameDescription
Quality of life assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL).Assessed at baseline and after 1 month of treatmentChange from baseline of quality of life as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.

Secondary

MeasureTime frameDescription
IBS Symptom SeverityAssessed at baseline and after 1 month of treatmentChange of IBS Symptom Severity assessed with the IBS Severity Scoring System (IBS-SSS, scoring from 0 to 500, with higher scores indicating worse severity of IBS symptoms)
Change of Stool consistencyAssessed at baseline, day10, day 20 and day 30Change of stool consistency assessed with the Bristol stool scale. The Bristol Stool Chart classifies stool according to their shape and consistency and assigns a sample a number from 1-7 depending on its characteristics, corresponding to constipation normal or diarrhea.
Compliance to the treatmentAssessed after 1 month of treatmentCompliance assessed with patient self-report on a diary
Quality of life subscores assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL).Assessed at baseline and after 1 month of treatmentChange from baseline of quality of life subscores as assessed with the Irritable Bowel Syndrome Quality Of Life questionnaire (IBS-QOL, scoring from 0 to 100, with higher scores indicating better IBS specific quality of life) in IBS patients having different subtypes of transit pattern and different level of symptom severity.
Patient's overall impression after treatmentAssessed after 1 month of treatmentThe patient's overall impression of how the product has changed his or her daily activities, symptoms, and quality of life, assessed with the Patients' Global Impression of Change (PGIC) scale. PGIC is a 7-point scale describing patient's rating of overall improvement. Change is rated by patients as very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Physician's satisfactionAssessed after 1 month of treatmentPhysician satisfaction with the treatment for his/her patient assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied
Patient satisfactionAssessed after 1 month of treatmentPatient satisfaction with treatment assessed on a 5-point Likert scale, with proposals ranked in ascending order of satisfaction as 1- Not at all satisfied; 2- Unsatisfied; 3- Somewhat satisfied; 4-Satisfied to 5-Very satisfied

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026